Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

Simple item page
dc.contributor.authorVillaseca, P
dc.contributor.authorHormaza, P
dc.contributor.authorCardenas, C
dc.contributor.authorOestreicher, E
dc.contributor.authorArteaga, E
dc.date.accessioned2024-01-10T12:05:18Z
dc.date.available2024-01-10T12:05:18Z
dc.date.issued2004
dc.description.abstractObjective Ethinylestradiol (EE) combined with the antiandrogenic progestin cyproterone acetate (CPA) is a possible treatment in polycystic ovary syndrome (PCOS). We investigated the impact of EE/CPA on lipid and carbohydrate metabolism in women with PCOS,who were otherwise healthy.
dc.description.abstractMethod The 31 women were separated into two groups paired by body mass index (BMI): Group A (control, n = 15) were cycled with 10 mg medroxyprogesterone acetate (MPA) x 10 days (Provera(R), Pharmacia & Upjohn) every month for 3 months; Group B (n = 16) were treated with 35 mug EE/2 mg CPA (Diane 35(R), Schering) for 3 months. Metabolic and hormonal conditions were similar in both groups.
dc.description.abstractResults Group A showed no change in any hormone or metabolic parameter. Group B showed a significant decrease in free androgen index (-81%) and increase in sex hormone binding globulin (+639%), a decrease in low density lipoprotein cholesterol (-14%) and total cholesterol/high density lipoprotein (HDL) cholesterol index (-19%), and increases in HDL cholesterol (+23%) and triglycerides (+82%) (p < 0.001). Fasting insulin increased in 18%, the glucose/insulin index worsened in 8%, and the plasma glucose disappearance worsened in 12%, with no statistical significance (p = 0.092, p = 0.308 and p = 0.237, respectively).
dc.description.abstractConclusion Treatment of PCOS with EE/CPA induces important favorable changes regarding hormone parameters associated with hyperandrogenism, significant favorable changes in lipid profile except for triglyceride increase, and no significant change in carbohydrate metabolism (measured by fasting insulin, glucose/insulin index and plasma glucose disappearance). MPA cycling does not change any of these parameters.
dc.fechaingreso.objetodigital2024-05-09
dc.format.extent11 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1080/13625180400007751
dc.identifier.issn1362-5187
dc.identifier.pubmedidMEDLINE:15697105
dc.identifier.urihttps://doi.org/10.1080/13625180400007751
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75985
dc.identifier.wosidWOS:000225273400005
dc.information.autorucMedicina;Arteaga E;S/I;98586
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final165
dc.pagina.inicio155
dc.publisherPARTHENON PUBLISHING GROUP
dc.revistaEUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
dc.rightsacceso restringido
dc.subjectpolycystic ovary syndrome
dc.subjectinsulin resistance
dc.subjectlipoproteins
dc.subjecthyperandrogenism
dc.subjectoral contraceptives
dc.subjectcyproterone acetate
dc.subjectmedroxyprogesterone acetate
dc.subjectHORMONE-BINDING GLOBULIN
dc.subjectCOMBINED ORAL-CONTRACEPTIVES
dc.subjectCYPROTERONE-ACETATE
dc.subjectINSULIN ACTION
dc.subjectESTROGEN REGIMENS
dc.subjectFREE TESTOSTERONE
dc.subjectGLUCOSE CLAMP
dc.subjectOBESE WOMEN
dc.subjectRESISTANCE
dc.subjectMETFORMIN
dc.subject.ods05 Gender Equality
dc.subject.odspa05 Igualdad de género
dc.titleEthinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes
dc.typeartículo
dc.volumen9
sipa.codpersvinculados98586
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-09. Ethinylestradiol-cyproterone acetate in polycystic ovary syndrome - lipid and carbohydrate changes.pdf
Size:
3.38 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas